Get started
Author

John Gordon Lenehan

Observed names: J Lenehan, J. LENEHAN, J.G. Lenehan, John G Lenehan, John G. Lenehan, John Lenehan, Lenehan, John, Lenehan, John G.
Observed institutions: Ontario Institute for Cancer Research, University of North Carolina at Chapel Hill, Western University, Lawson Health Research Institute, London Health Sciences Centre, Victoria Hospital, London Health Sciences Centre Research Institute
ORCID: 0000-0002-6225-3973
Observed ORCID: 0000-0002-6225-3973
OpenAlex ID: A5058320099
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Bertrand Routy, John G. Lenehan, et al. · Nature Medicine · 516
An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics
2008 · James S. Duncan, Laszlo Gyenis, et al. · Molecular & Cellular Proteomics · 88
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
2026 · Sreya Duttagupta, Meriem Messaoudene, et al. · Nature Medicine · 85
PDF
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
2015 · W A Teft, S Welch, et al. · British Journal of Cancer · 78
PDF
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
2020 · Mithunah Krishnamoorthy, John G Lenehan, et al. · JNCI Journal of the National Cancer Institute · 76
PDF
Women’s Knowledge, Attitudes, and Intentions Concerning Human Papillomavirus Vaccination: Findings of a Waiting Room Survey of Obstetrics-Gynaecology Outpatients
2008 · John G. Lenehan, Kevin C. Leonard, et al. · Journal of Obstetrics and Gynaecology Canada · 47
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
2021 · Theodore J. Wigle, Brandi L. Povitz, et al. · Clinical and Translational Science · 45
PDF
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial
2026 · Ricardo Fernandes, Behnam Jabbarizadeh, et al. · Nature Medicine · 38
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
2025 · Danial Khan Hadi, Kelly J Baines, et al. · Journal for ImmunoTherapy of Cancer · 36
PDF
Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma
2021 · Adi Kartolo, Jasna Deluce, et al. · Journal of Immunotherapy · 23
1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
2024 · A. Elkrief, S. Duttagupta, et al. · Annals of Oncology · 22
PDF
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients
2020 · Adrienne E. Borrie, Finnley A. Rose, et al. · Breast Cancer Research and Treatment · 20
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer
2018 · Adrienne E. Borrie, Rhiannon V. Rose, et al. · Breast Cancer Research and Treatment · 17
Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series
2007 · J.S. KWON, J. LENEHAN, et al. · International Journal of Gynecological Cancer · 17
Abstract CT258: Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)
2024 · Sreya Duttagupta, Meriem Messaoudene, et al. · Cancer Research · 13
Immunomodulation in Pancreatic Cancer
2020 · Mithunah Krishnamoorthy, John G. Lenehan, et al. · Cancers · 13
PDF
P864 Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients
2020 · Saman Maleki, John Lenehan, et al. · Poster presentations · 12
PDF
Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma.
2022 · Wilson H. Miller, Bertrand Routy, et al. · Journal of Clinical Oncology · 11
Enhanced donor screening for faecal microbial transplantation during COVID-19
2021 · Seema Nair Parvathy, John G Lenehan, et al. · Gut · 10
PDF
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Bertrand Routy, John G. Lenehan, et al. · Nature Medicine · 9
PDF
Abstract 2210: Microbiome profiling reveals that fecal microbiota transplantation (FMT) modulates response and toxicity when combined with immunotherapy in patients with lung cancer and melanoma (FMT-LUMINate NCT04951583)
2025 · Sreya Duttagupta, Meriem Messaoudene, et al. · Cancer Research · 7
An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and Identification of Novel Inhibitor Targets
2021 · Litchfield, David W., Gyenis, Laszlo, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 6
PDF
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
2026 · Déborah Suissa, Marine Fidelle, et al. · Nature Medicine · 5
PDF
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
2016 · John Gordon Lenehan, Wendy A. Teft, et al. · Journal of Clinical Oncology · 5
614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
2022 · Bertrand Routy, John Lenehan, et al. · Regular and Young Investigator Award Abstracts · 4
PDF
Works count: 47
Citation count: 1,215
H-index: 14
I10-index: 19
Year
Topic
Type